{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T04:16:51Z","timestamp":1687580211299},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Private Universit\u00e4t Witten\/Herdecke gGmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Einleitung<\/jats:title>\n                <jats:p>Um der COVID-19-Pandemie entgegenzuwirken, wurden seit Dezember 2020 mehrere SARS-CoV-2-Impfstoffe zugelassen. Kurz nach Beginn der Impfkampagnen wurden einzelne allergische Reaktionen nach Vakzination beschrieben, was zu Unsicherheit vieler Patienten mit positiver allergologischer Anamnese gef\u00fchrt hat. Ziel dieser Arbeit war es zu erfassen, welche anamnestischen Ereignisse als Anlass f\u00fcr eine allergologische Abkl\u00e4rung vor COVID-19-Impfung dienten und welche Ergebnisse die entsprechende allergologische Diagnostik geliefert hat.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methoden<\/jats:title>\n                <jats:p>Es erfolgte eine retrospektive Datenanalyse aller Patienten, die sich w\u00e4hrend der Jahre 2021 und 2022 im Zentrum f\u00fcr Dermatologie, Allergologie und Dermatochirurgie des Helios Universit\u00e4tsklinikums Wuppertal zur allergologischen Beratung oder Abkl\u00e4rung vor COVID-19-Vakzinierung vorstellten. Es wurden demografische Daten, allergologische Anamnese, Anlass der Konsultation in der Klinik und Ergebnisse allergologischer Diagnostik inklusive eventueller Reaktionen nach durchgef\u00fchrter Impfung erfasst.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Insgesamt stellten sich 93\u00a0Patienten zur allergologischen Abkl\u00e4rung in Bezug auf COVID-19-Vakzine vor. In etwa der H\u00e4lfte der F\u00e4lle erfolgte die Vorstellung in der Klinik aus Unsicherheit und Sorge vor allergischen Reaktionen und generellen Nebenwirkungen. Darunter waren 26,9\u202f% (25\/93) Patienten, die bisher noch keine COVID-19-Impfung erhalten hatten, und weitere 23,7\u202f% (22\/93), die eine nichtallergische Reaktion nach der bereits erfolgten COVID-19-Impfung (z.\u202fB. Kopfschmerzen, Sch\u00fcttelfrost, Fieber, Unwohlsein etc.) erlitten haben; 46,2\u202f% (43\/93) der Patienten wurden aufgrund einer komplexen allergologischen Vorgeschichte in der Klinik geimpft. Dabei traten keine allergischen Reaktionen auf. Lediglich 1\u00a0Patientin mit bekannter chronisch-spontaner Urtikaria entwickelte mehrere Stunden nach Impfung ein Angio\u00f6dem der Lippen, welches wir als nichtallergische Exazerbation der Grunderkrankung werteten. Den verbliebenen 53,8\u202f% (50\/93) der Patienten wurde eine ambulante Impfung in der Hausarztpraxis empfohlen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Diskussion<\/jats:title>\n                <jats:p>Allergische Reaktionen nach COVID-19-Impfstoffen sind selten, viele Patienten mit positiver allergologischer Anamnese haben jedoch Sorgen, nach der COVID-19-Vakzination allergisch zu reagieren. \u00d6ffentlichkeitsarbeit im Rahmen von Impfkampagnen durch allergologisch t\u00e4tige \u00c4rzte ist notwendig, um den Sorgen und \u00c4ngsten der Bev\u00f6lkerung \u2013\u00a0und insbesondere Patienten mit Allergien in der Anamnese\u00a0\u2013 gerecht zu werden.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00105-023-05152-3","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T14:03:19Z","timestamp":1683208999000},"page":"511-519","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gr\u00fcnde f\u00fcr allergologische Diagnostik und deren Ergebnisse im Kontext von COVID-19-Vakzinierungen","Reasons for allergology consultations prior to COVID-19 vaccination and their outcomes"],"prefix":"10.1007","volume":"74","author":[{"given":"Eleni","family":"Leonidou Floru\u00df","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasiia","family":"Demidova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke C.","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galina","family":"Balakirski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,4]]},"reference":[{"key":"5152_CR1","first-page":"8","volume":"15","author":"J Schilling","year":"2021","unstructured":"Schilling\u00a0J, Buda\u00a0S, Fischer\u00a0M, Goerlitz\u00a0L, Grote\u00a0U, Haas\u00a0W, Hamouda\u00a0O, Prahm\u00a0K, Tolksdorf\u00a0K (2021) Retrospektive Phaseneinteilung der COVID-19-Pandemie in Deutschland bis Februar 2021. Epid Bull 15:8\u201317","journal-title":"Epid Bull"},{"key":"5152_CR2","unstructured":"https:\/\/www.pei.de\/DE\/arzneimittel\/impfstoffe\/covid-19\/covid-19-node.html. Zugegriffen: 1. Jan. 2023"},{"issue":"8","key":"5152_CR3","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1001\/jama.2021.0600","volume":"325","author":"T Shimabukuro","year":"2021","unstructured":"Shimabukuro\u00a0T, Nair\u00a0N (2021) Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-biontech COVID-19 vaccine. JAMA 325(8):780\u2013781","journal-title":"JAMA"},{"issue":"3","key":"5152_CR4","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/ajt.16517","volume":"21","author":"T Shimabukuro","year":"2021","unstructured":"Shimabukuro\u00a0T (2021) Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine\u2014United States, December 21, 2020-January 10, 2021. Am J Transplant 21(3):1326\u20131331","journal-title":"Am J Transplant"},{"issue":"2","key":"5152_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s15007-021-4762-4","volume":"30","author":"L Klimek","year":"2021","unstructured":"Klimek\u00a0L, Novak\u00a0N, Hamelmann\u00a0E, Werfel\u00a0T, Wagenmann\u00a0M et al (2021) Schwere allergische Reaktionen nach COVID-19-Impfung mit dem Impfstoff von Pfizer\/BioNTech in Gro\u00dfbritannien und USA: Stellungnahme der deutschen allergologischen Gesellschaften AeDA (\u00c4rzteverband Deutscher Allergologen), DGAKI (Deutsche Gesellschaft f\u00fcr Allergologie und klinische Immunologie) und GPA (Gesellschaft f\u00fcr P\u00e4diatrische Allergologie und Umweltmedizin). Allergo\u00a0J 30(2):24\u201329","journal-title":"Allergo J"},{"key":"5152_CR6","unstructured":"https:\/\/dgaki.de\/wp-content\/uploads\/2021\/01\/Impf_info_A4_web_neu.pdf. Zugegriffen: 1. Jan. 2023"},{"issue":"1","key":"5152_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s15006-021-9530-6","volume":"163","author":"M Worm","year":"2021","unstructured":"Worm\u00a0M, Ring\u00a0J, Klimek\u00a0L, Jakob\u00a0J, Lange\u00a0L et al (2021) Covid-19 vaccination and risk of anaphylaxis\u2014Recommendations for practical management. MMW Fortschr Med 163(1):48\u201351","journal-title":"MMW Fortschr Med"},{"key":"5152_CR8","unstructured":"COVID-19 Impfquoten-Monitoring in Deutschland (COVIMO), Report 10 vom 14. April 2022. https:\/\/www.rki.de\/DE\/Content\/InfAZ\/N\/Neuartiges_Coronavirus\/Projekte_RKI\/COVIMO_Reports\/covimo_studie_bericht_10.pdf?__blob=publicationFile. Zugegriffen: 1. Jan. 2023"},{"issue":"6","key":"5152_CR9","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1111\/all.12142","volume":"68","author":"K Brockow","year":"2013","unstructured":"Brockow\u00a0K, Garvey\u00a0LH, Aberer\u00a0W, Atanaskovic-Markovic\u00a0M, Barbaud\u00a0A et al (2013) Skin test concentrations for systemically administered drugs\u2014an ENDA\/EAACI Drug Allergy Interest Group position paper. Allergy 68(6):702\u2013712","journal-title":"Allergy"},{"issue":"8","key":"5152_CR10","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1055\/s-0030-1256476","volume":"65","author":"F Ru\u00ebff","year":"2011","unstructured":"Ru\u00ebff\u00a0F, Bergmann\u00a0KC, Brockow\u00a0K, Fuchs\u00a0T, Gr\u00fcbl\u00a0A et al (2011) Skin tests for diagnostics of allergic immediate-type reactions. Guideline of the German Society for Allergology and Clinical Immunology. Pneumologie 65(8):484\u2013495","journal-title":"Pneumologie"},{"issue":"10","key":"5152_CR11","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1016\/j.jaip.2021.06.006","volume":"9","author":"M Greenhawt","year":"2021","unstructured":"Greenhawt\u00a0M, Abrams\u00a0EM, Shaker\u00a0M, Chu\u00a0DK, Khan\u00a0D et al (2021) The risk of allergic reaction to SARS-CoV\u20112 vaccines and recommended evaluation and management: a systematic review, meta-analysis, GRADE assessment, and international consensus approach. J\u00a0Allergy Clin Immunol Pract 9(10):3546\u20133567","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"5152_CR12","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden\u00a0LR, El Sahly\u00a0HM, Essink\u00a0B, Kotloff\u00a0K, Frey\u00a0S et al (2021) Efficacy and safety of the mRNA-1273 SARS-CoV\u20112 vaccine. N\u00a0Engl J Med 384(5):403\u2013416","journal-title":"N Engl J Med"},{"issue":"25","key":"5152_CR13","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1056\/NEJMoa2105290","volume":"385","author":"AR Falsey","year":"2021","unstructured":"Falsey\u00a0AR, Sobieszczyk\u00a0ME, Hirsch\u00a0I, Sproule\u00a0S, Robb\u00a0ML et al (2021) Phase 3 safety and efficacy of AZD1222 (ChAdox1 nCoV-19) Covid-19 vaccine. N\u00a0Engl J Med 385(25):2348\u20132360","journal-title":"N Engl J Med"},{"issue":"11","key":"5152_CR14","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.1016\/j.jaip.2021.08.039","volume":"9","author":"LM Fijen","year":"2021","unstructured":"Fijen\u00a0LM, Levi\u00a0M, Cohn\u00a0DM (2021) COVID-19 vaccination and the risk of swellings in patients with hereditary angioedema. J\u00a0Allergy Clin Immunol Pract 9(11):4156\u20134158","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"5152_CR15","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1111\/all.14739","volume":"76","author":"M Sokolowska","year":"2021","unstructured":"Sokolowska\u00a0M, Eiwegger\u00a0T, Ollert\u00a0M et al (2021) EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines. Allergy 76(6):1629\u20131639","journal-title":"Allergy"},{"issue":"3","key":"5152_CR16","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.alit.2021.04.003","volume":"70","author":"B Cabanillas","year":"2021","unstructured":"Cabanillas\u00a0B, Novak\u00a0N (2021) Allergy to COVID-19 vaccines: A current update. Allergol Int 70(3):313\u2013318","journal-title":"Allergol Int"},{"key":"5152_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.5414\/ALX02225E","volume":"5","author":"M Worm","year":"2021","unstructured":"Worm\u00a0M, Bauer\u00a0A, Wedi\u00a0B, Treudler\u00a0R, Pfuetzner\u00a0W et al (2021) Practical recommendations for the allergological risk assessment of the COVID-19 vaccination\u2014a\u00a0harmonized statement of allergy centers in Germany. Allergol Sel 5:72\u201376","journal-title":"Allergol Sel"},{"issue":"9","key":"5152_CR18","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1016\/j.jaip.2021.06.010","volume":"9","author":"AR Wolfson","year":"2021","unstructured":"Wolfson\u00a0AR, Robinson\u00a0LB, Li\u00a0L et al (2021) First-dose mRNA COVID-19 vaccine allergic reactions: limited role for excipient skin testing. J\u00a0Allergy Clin Immunol Pract 9(9):3308\u20133320","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"5152_CR19","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1111\/all.15241","volume":"77","author":"A Barbaud","year":"2022","unstructured":"Barbaud\u00a0A, Garvey\u00a0LH, Arcolaci\u00a0A et al (2022) Allergies and COVID-19 vaccines: An ENDA\/EAACI Position paper. Allergy 77(8):2292\u20132312","journal-title":"Allergy"},{"issue":"11","key":"5152_CR20","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1111\/all.15038","volume":"76","author":"A Kessel","year":"2021","unstructured":"Kessel\u00a0A, Bamberger\u00a0E, Nachshon\u00a0L et al (2021) Safe administration of the Pfizer-BioNtTech COVID-19 vaccine following an immediate reaction to the first dose. Allergy 76(11):3538\u20133540","journal-title":"Allergy"},{"issue":"5","key":"5152_CR21","doi-asserted-by":"publisher","first-page":"e12044","DOI":"10.1002\/clt2.12044","volume":"11","author":"TH Rasmussen","year":"2021","unstructured":"Rasmussen\u00a0TH, Mortz\u00a0CG, Georgsen\u00a0TK et al (2021) Patients with suspected allergic reactions to COVID-19 vaccines can be safely revaccinated after diagnostic work-up. Clin Transl Allergy 11(5):e12044","journal-title":"Clin Transl Allergy"},{"issue":"11","key":"5152_CR22","doi-asserted-by":"publisher","first-page":"3426","DOI":"10.1111\/all.15414","volume":"77","author":"M Worm","year":"2022","unstructured":"Worm\u00a0M, Alexiou\u00a0A, Bauer\u00a0A, Treudler\u00a0R, Wurpts\u00a0G et al (2022) Management of suspected and confirmed COVID-19 (SARS-CoV-2) vaccine hypersensitivity. Allergy 77(11):3426\u20133434","journal-title":"Allergy"},{"issue":"4","key":"5152_CR23","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1001\/jamainternmed.2021.8515","volume":"182","author":"DK Chu","year":"2022","unstructured":"Chu\u00a0DK, Abrams\u00a0EM, Golden\u00a0DBK et al (2022) Risk of second allergic reaction to SARS-CoV\u20112 vaccines: a systematic review and meta-analysis. JAMA Intern Med 182(4):376\u2013385","journal-title":"JAMA Intern Med"},{"issue":"6","key":"5152_CR24","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.anai.2022.09.001","volume":"129","author":"M Greenhawt","year":"2022","unstructured":"Greenhawt\u00a0M (2022) Is there value in coronavirus disease 2019 vaccine and vaccine excipient skin testing or split dosing? Ann Allergy Asthma Immunol 129(6):667\u2013668","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"10","key":"5152_CR25","first-page":"1359","volume":"20","author":"S Forkel","year":"2022","unstructured":"Forkel\u00a0S, Beutner\u00a0C, Buhl\u00a0T (2022) Anxiety and limited understanding are the main reasons for refusing drug challenge tests. J\u00a0Dtsch Dermatol Ges 20(10):1359\u20131361","journal-title":"J Dtsch Dermatol Ges"},{"issue":"10","key":"5152_CR26","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S2213-2600(21)00370-2","volume":"9","author":"EM Abrams","year":"2021","unstructured":"Abrams\u00a0EM, Shaker\u00a0M, Sinha\u00a0I, Greenhawt\u00a0M (2021) COVID-19 vaccines: addressing hesitancy in young people with allergies. Lancet Respir Med 9(10):1090\u20131092","journal-title":"Lancet Respir Med"},{"issue":"28","key":"5152_CR27","doi-asserted-by":"publisher","first-page":"997","DOI":"10.15585\/mmwr.mm7028e1","volume":"70","author":"AM Scherer","year":"2021","unstructured":"Scherer\u00a0AM, Gedlinske\u00a0AM, Parker\u00a0AM et al (2021) Acceptability of adolescent COVID-19 vaccination among adolescents and parents of adolescents\u2014United States, April 15\u201323, 2021. Mmwr Morb Mortal Wkly Rep 70(28):997\u20131003","journal-title":"Mmwr Morb Mortal Wkly Rep"},{"issue":"1","key":"5152_CR28","doi-asserted-by":"publisher","first-page":"ofab584","DOI":"10.1093\/ofid\/ofab584","volume":"9","author":"M Greenhawt","year":"2021","unstructured":"Greenhawt\u00a0M, Abrams\u00a0EM, Shaker\u00a0M (2021) Allergists can safely evaluate and revaccinate individuals with immediate allergic reactions to mRNA COVID-19 vaccines. Open Forum Infect Dis 9(1):ofab584","journal-title":"Open Forum Infect Dis"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-023-05152-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-023-05152-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-023-05152-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T21:29:46Z","timestamp":1687555786000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-023-05152-3"}},"subtitle":["2-j\u00e4hrige Erfahrung eines Allergiezentrums in Nordrhein-Westfalen","Two-year experience of an allergy center in North Rhine\u2013Westphalia"],"short-title":[],"issued":{"date-parts":[[2023,5,4]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["5152"],"URL":"https:\/\/doi.org\/10.1007\/s00105-023-05152-3","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,4]]},"assertion":[{"value":"3 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"E.\u00a0Leonidou, A.\u00a0Demidova, S.C.\u00a0Hofmann und G.\u00a0Balakirski geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}